• ω-Agatoxin IVA and Excitotoxicity in Cortical Neurons

  2026-08-07

  Lustig, Ahern, and Greenberg tested whether blocking P/Q-type calcium channels with ω-agatoxin IVA could protect cultured cortical neurons from acute excitotoxic injury triggered by veratridine, ouabain, or NMDA. The antagonist failed to reduce LDH-defined toxicity at concentrations below 300 nM, showing that inhibition of presynaptic glutamate release does not necessarily prevent downstream neuronal injury.

• Nile Red (SKU B8209): Optimizing Lipid Droplet Assays in Cel

  2026-08-07

  This article delivers scenario-driven, evidence-based guidance for optimizing intracellular lipid droplet staining using Nile Red (SKU B8209). Drawing on validated workflows and recent literature, it addresses common laboratory challenges in lipid metabolism research and highlights the reliability and performance advantages of APExBIO's Nile Red.

• Bone Transport Promotes Diabetic Foot Healing via TGF-β1 Pat

  2026-08-06

  This study reveals that bone transport (BT) accelerates diabetic foot ulcer healing by activating the TGF-β1/TGFBR1 signaling axis, effectively coupling angiogenesis, osteogenesis, and immunomodulation. These findings clarify the molecular mechanisms underlying BT’s therapeutic effects and highlight TGF-β1 pathway modulation as a promising strategy for chronic wound repair.

• ETS1 Modulates SUMOylation-Dependent Mitophagy in BPD Models

  2026-08-06

  This study reveals that ETS1, a transcription factor, protects against bronchopulmonary dysplasia (BPD) by inhibiting mitochondrial damage-induced autophagy through the SENP2/HSPA8/FUNDC1 axis. By elucidating the mechanistic link between SUMOylation and mitophagy, the research provides a molecular basis for targeted interventions in neonatal lung disease.

• A 83-01 (ALK-5 Inhibitor): Precision Control in TGF-β Assays

  2026-08-05

  Explore how A 83-01, a potent ALK-5 inhibitor, enables advanced TGF-β signaling pathway interrogation and practical assay optimization. This article uniquely examines benchmark organoid research and protocol parameters, offering distinct insights for experimental design.

• Hyaluronic Acid Sodium Salt: A Translational Nexus for ECM M

  2026-08-05

  Explore how hyaluronic acid sodium salt advances extracellular matrix engineering and nanoparticle-mediated immune modulation, with mechanistic insights and actionable strategies for translational research. This article synthesizes evidence from cutting-edge infection models and nanoparticle delivery systems, positioning APExBIO’s product as an indispensable platform for next-generation workflows.

• LY364947: Transforming TGF-β Inhibition into Translational I

  2026-08-04

  Explore how LY364947, a selective TGF-β type I receptor kinase inhibitor, empowers translational researchers to dissect and modulate TGF-β-driven EMT, fibrosis, and retinal degeneration. Drawing on recent mechanistic insights—including cross-talk with Wnt/β-catenin signaling in pancreatic cancer—we provide actionable workflow guidance and a strategic perspective on leveraging advanced TGF-β pathway modulation.

• LMCD1 Drives Corneal Fibrosis via TGF-β1/SMAD3: Mechanistic

  2026-08-04

  This study uncovers LIM and cysteine-rich domains-1 (LMCD1) as a key mediator in TGF-β1-induced corneal myofibroblast differentiation and fibrosis. The findings clarify the SMAD3-dependent upregulation of LMCD1 in both cell and animal models, offering new mechanistic targets for controlling corneal fibrosis.

• Etomoxir (SKU A3404): Data-Backed Solutions for Immunometabo

  2026-08-03

  This article delivers scenario-driven, evidence-based guidance for biomedical researchers using Etomoxir (SKU A3404) in immunometabolic workflows. Drawing on protocol references and real lab challenges, it clarifies how Etomoxir’s validated inhibition of CPT-1 enables reliable fatty acid oxidation pathway research. Practical Q&A blocks help labs optimize protocols, interpret assay data, and make informed product selections.

• Verteporfin (CL 318952): Mechanisms and Research Application

  2026-08-03

  Verteporfin, also known as CL 318952, is a second-generation photosensitizer pivotal for photodynamic therapy in ocular neovascularization. Its dual mechanism—light-activated vascular occlusion and light-independent autophagy inhibition—enables highly selective cell targeting with minimal systemic toxicity. This article details the molecular basis, protocol benchmarks, and practical limitations for research use.

• SIS3 (Smad3 Inhibitor): Unraveling TGF-β/Smad3 Pathway Compl

  2026-08-02

  Explore how SIS3, a potent Smad3 inhibitor, enables advanced dissection of the TGF-β/Smad3 signaling axis in fibrosis and cancer research. This article offers new insights into mechanistic selectivity, translational relevance, and practical assay design.

• WP1066 and Precision JAK2/STAT3 Inhibition in Advanced Cance

  2026-08-01

  Explore how WP1066, a potent JAK2/STAT3 inhibitor, enables advanced cancer and regenerative research. This article uniquely details mechanistic depth, translational assay strategy, and the evolving role of JAK2/STAT3 targeting in both oncology and immunoregenerative scaffolds.

• Ridaforolimus (Deforolimus): Unveiling mTOR Inhibitor Precis

  2026-07-31

  Explore how Ridaforolimus (Deforolimus) revolutionizes apoptosis assays and anti-angiogenic strategies in advanced cancer research. This article uniquely delves into quantitative mTOR pathway targeting, practical protocol optimization, and the impact of AI-driven senolytic discovery.

• AT-406 (SM-406): Redefining Apoptosis Pathway Activation in

  2026-07-31

  This thought-leadership article dissects the mechanistic and strategic imperatives of targeting inhibitor of apoptosis proteins (IAPs) in cancer research, focusing on AT-406 (SM-406). Integrating new structural insights into death receptor complex assembly with real-world translational guidance, it empowers oncology researchers to leverage AT-406 for precision apoptosis modulation, chemotherapeutic sensitization, and preclinical model optimization.

• TBXA2R-ERM Axis Drives Metastatic Motility in TNBC Cells

  2026-07-30

  The reference study uncovers a mechanistic link between thromboxane A2 receptor (TBXA2R) activation and ERM protein–mediated motility, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. By delineating the downstream signaling cascade involving G proteins, Rho GTPases, and kinase effectors, the research provides new insights into GPCR-driven cytoskeletal remodeling and identifies actionable targets for metastasis intervention.

15286 records 1/1020 page Next 12345 下5页 Last page